Nanollose Limited (ASX:NC6) is pleased to announce that the Company has signed a non-binding Memorandum of Understanding (MoU) with Indonesian food producer, PT Supra Natami Utama (PT SNU).
The board of Queensland Bauxite Limited (ASX:QBL) is pleased to update the market on developments in the drug development strategy for its subsidiary, Medical Cannabis Limited. MCL, in conjunction with Certara, a pharmaceutical consulting firm, have developed a drug development strategy for the distribution of Canntab XR medication in the Australian market.
The Board of Queensland Bauxite (ASX:QBL) is pleased to advise that it has cleared the company's outstanding debt by way of share issue.
The Directors present their report on Queensland Bauxite Limited, consisting of Queensland Bauxite Limited (ASX:QBL) and the entities it controlled at the end of or during the half-year ended 31 December 2017.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced that the previously reported positive results from its Phase 1 safety trial of Progenza in patients with knee osteoarthritis have been published in the Journal of Translational Medicine.
The Board of Queensland Bauxite Limited (ASX:QBL) is pleased to announce that its subsidiary company Medical Cannabis Limited through its wholly owned subsidiary Medical Cannabis Research Group Pty Ltd, has signed a Research Funding Agreement with the Research & Development Foundation at the Technion Institute, Haifa, Israel.
Anatara Lifesciences (ASX:ANR) today released its Appendix 4D financial report for the half year ending 31st December 2017.
